Max Healthcare Institute Limited has informed the Exchange about copy of newspaper publication for standalone and consolidated financial results for the quarter and financial year ended March 31, 2025
MAXHEALTH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Max Healthcare has published its Q4 and full-year FY25 financial results (year ended March 31, 2025). Consolidated revenue from operations rose to ₹190,974 lakhs in Q4 FY25 (vs ₹142,290 lakhs in Q4 FY24), with full-year FY25 revenue at ₹702,846 lakhs vs ₹540,602 lakhs — roughly 30% year-on-year growth. Consolidated profit after tax for FY25 was ₹107,588 lakhs (vs ₹105,764 lakhs), with basic EPS of ₹11.07. Standalone FY25 revenue was ₹266,360 lakhs and PAT was ₹70,107 lakhs. The results include the full integration of Jaypee Healthcare (acquired for ~₹625 crore in Oct–Nov 2024, goodwill of ₹56,178 lakhs) and the merger of subsidiary ALPS Hospital, effective March 28, 2025. The Board has recommended a dividend of ₹1.50 per share (15% of face value) for FY25, subject to shareholder approval.
Strong revenue growth, largely supported by the Jaypee Healthcare acquisition, with steady margins and a modest dividend — a positive signal for shareholders. Continued consolidation of subsidiaries points to future synergy and cost benefits.